Phenylhydrazines
Medchemexpress LLC AG-636 | 1623416-31-8 | 98.07% | 343.38 | 1 ML
AG-636 is a potent, reversible, selective, and orally active dihydroorotate dehydrogenase (DHODH) inhibitor. With an IC50 of 17 nM, it demonstrates strong anticancer effects and growth-inhibitory activity in various cancer cell lines. It has also shown robust tumor growth inhibition in xenograft lymphoma models.
- Potent, reversible, selective, and orally active DHODH inhibitor
- IC50 of 17 nM against DHODH
- Strong growth-inhibitory activity in cancer cell lines of hematologic versus solid tumor origin
- Robust tumor growth inhibition in xenograft lymphoma models
- Currently in phase 1 clinical trial for lymphoma
Medchemexpress LLC AG-636 | 1623416-31-8 | 98.07% | 343.38 | 25 MG
AG-636 is a potent, reversible, selective, and orally active dihydroorotate dehydrogenase (DHODH) inhibitor. It demonstrates strong anticancer effects by inhibiting DHODH with an IC50 of 17 nM.
- Potent, reversible, selective, and orally active DHODH inhibitor
- Inhibits dihydroorotate dehydrogenase (DHODH) with an IC50 of 17 nM
- Exhibits strong growth-inhibitory activity in cancer cell lines
- Demonstrates robust tumor growth inhibition in xenograft lymphoma tumor models
Medchemexpress LLC AG-636 | 1623416-31-8 | 98.1% | 343.38 | 5 MG
AG-636 is a potent, reversible, selective, and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 17 nM. It demonstrates strong anticancer effects.
- Exhibits strong growth-inhibitory activity in cancer cell lines of both hematologic and solid tumor origin.
- Functions as a dihydroorotate dehydrogenase (DHODH) inhibitor.
- Applications:
- In vitro: has shown strong growth-inhibitory activity in various cancer cell lines.
- In vivo: treatment resulted in robust tumor growth inhibition in the OCILY19 DLBCL tumor xenograft model.
- Clinical trials: being investigated in a Phase 1 clinical trial (NCT03834584) for lymphoma, which started on May 24, 2019.
Medchemexpress LLC Pioglitazone hydrochloride | 112529-15-4 | 100.0% | C19H21ClN2O3S | 1 ML
Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. It can ameliorate insulin resistance and diabetes, attenuates the loss of body weight and cardiac hypertrophy, reduces elevated serum glucose levels, and improves associated dyslipidemia. In vitro, it completely abrogates AGEs-induced beta cell necrosis and prevents AGEs-induced increment in caspase-3 activation.
- Potent and selective PPARγ agonist
- Ameliorates insulin resistance and diabetes
- Attenuates loss of body weight and cardiac hypertrophy
- Reduces elevated serum glucose levels
- Improves associated dyslipidemia
- Completely abrogates AGEs-induced beta cell necrosis
- Prevents AGEs-induced increment in caspase-3 activation